Cargando…
Medical Advances in Hepatitis D Therapy: Molecular Targets
An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of the disease. Until re...
Autores principales: | Vogt, Amelie, Wohlfart, Sabrina, Urban, Stephan, Mier, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506394/ https://www.ncbi.nlm.nih.gov/pubmed/36142728 http://dx.doi.org/10.3390/ijms231810817 |
Ejemplares similares
-
Mass Spectrometric Quantification of the Antimicrobial Peptide Pep19-2.5 with Stable Isotope Labeling and Acidic Hydrolysis
por: Wohlfart, Sabrina, et al.
Publicado: (2021) -
Interplay between Hepatitis D Virus and the Interferon Response
por: Zhang, Zhenfeng, et al.
Publicado: (2020) -
Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor
por: Schieck, Alexa, et al.
Publicado: (2010) -
Molecular targeted therapies for breast cancer treatment
por: Schlotter, Claus M, et al.
Publicado: (2008) -
Molecular targeted therapy for advanced gastric cancer
por: Kim, Jong Gwang
Publicado: (2013)